Treatment of varicella-zoster virus infections with adenine arabinoside.

Abstract

Twenty-three patients with complicated varicella-zoster virus infections were treated with adenine arabinoside. Of 14 patients with herpes zoster, 13 had malignancy treated with irradiation and cytotoxic agents or steroids. Although the duration of active vesicle formation in these patients ranged from two to 14 days before therapy, no new lesions appeared after the fourth day of treatment with adenine arabinoside. Zoster encephalitis developed in one patient on the third day of treatment, and severe postherpetic neuralgia was seen in three patients. Of nine treated patients with primary varicella, six improved, including five with evidence of varicella pneumonia. Two of the three patients with varicella who died were immunosuppressed and had progressive viral pneumonia with persistently high titers of virus in vesicular fluid; the third pateint was a child with Reye's syndrome. Double-blind controlled studies will be necessary to demonstrate the efficacy of adenine arabinoside in the treatment of infections with varicella-zoster virus.

• Authors: M T Johnson, R A Buchanan, J P Luby, D Mikulec
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 131 Issue 3 Pg. 225-9 (Mar 1975) ISSN: 0022-1899 [Print] United States
• PMID: 165242 (Publication Type: Journal Article)

Chemical References

• Hemoglobins
• Vidarabine

Topics

• Adult
• Blister (microbiology)
• Chickenpox (complications, drug therapy)
• Child
• Chronic Disease
• Encephalitis (complications)
• Female
• Hemoglobins
• Herpes Zoster (complications, drug therapy, radiotherapy)
• Herpesvirus 3, Human (isolation & purification)
• Humans
• Lung Diseases, Obstructive (complications)
• Male
• Pneumonia, Viral (complications)
• Recurrence
• Reye Syndrome (complications)
• Vidarabine (adverse effects, blood)
• Virus Replication